Hypogonadal men treated with oral testosterone undecanoate

Abstract

Three hypogonadal male subjects with very low plasma testosterone levels were given testosterone undecanoate orally (120 mg daily for 3 weeks) as a replacement therapy. Normal adult male testosterone plasma values were rapidly reached and attained throughout the therapy. Similar elevations of plasma androstenedione were noted. A reduction in sex hormone binding globulin following the therapy was observed. Satisfactory clinical responses were reported by the patients. We thank Organon Laboratories Ltd. for supplying TU and financial help with this project.